High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer

Forty women with metastatic breast cancer were randomized to receive either mitomycin-C (MMC) (21 patients) or vindesine (19 patients) with high dose medroxyprogesterone acetate (MPA). Response rates were not significantly different (33% for MPA and MMC and 28% for MPA and vindesine); the duration o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of clinical oncology 1988-08, Vol.11 (4), p.431-434
Hauptverfasser:	FALKSON, C. I, FALKSON, H. C, FALKSON, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - mortality Chemotherapy Female Humans Medical sciences Medroxyprogesterone - administration & dosage Medroxyprogesterone - adverse effects Medroxyprogesterone - analogs & derivatives Medroxyprogesterone Acetate Middle Aged Mitomycin Mitomycins - administration & dosage Mitomycins - adverse effects Pharmacology. Drug treatments Random Allocation Vindesine - administration & dosage Vindesine - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Forty women with metastatic breast cancer were randomized to receive either mitomycin-C (MMC) (21 patients) or vindesine (19 patients) with high dose medroxyprogesterone acetate (MPA). Response rates were not significantly different (33% for MPA and MMC and 28% for MPA and vindesine); the duration of response was better for patients receiving the MMC combination (median of 10.5 months versus 6 months for those on the vindesine combination).
ISSN:	0277-3732 1537-453X
DOI:	10.1097/00000421-198808000-00003